MedTrace Logo

The Holistic Study

NCT07051915 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2025-09-09

No results posted yet for this study

Summary

This study is a phase 3 study where eligible patients will be randomized 1:1 to one of two treatment strategies: receiving a thrombopoietin receptor agonist (Avatrombopag), or anti-CD20 (Rituximab).

Conditions

  • Thrombocytopenia Purpura

Interventions

DRUG

Avatrombopag

Daily tablets

DRUG

Rituximab (Arm B)

I.V.

Sponsors & Collaborators

  • Oslo University Hospital

    collaborator OTHER

  • University Hospital, Akershus

    collaborator OTHER

  • Sykehuset i Vestfold HF

    collaborator OTHER

  • St. Olavs Hospital

    collaborator OTHER

  • Helse Stavanger HF

    collaborator OTHER_GOV

  • Sorlandet Hospital HF

    collaborator OTHER_GOV

  • University Hospital of North Norway

    collaborator OTHER

  • Haukeland University Hospital

    collaborator OTHER

  • Helse Nord-Trøndelag HF

    collaborator OTHER

  • Helse Fonna

    collaborator OTHER

  • Nordlandssykehuset HF

    collaborator OTHER

  • Ostfold Hospital Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-15
Primary Completion
2028-01-31
Completion
2029-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07051915 on ClinicalTrials.gov